For years, chemotherapy was the backbone of triple-negative breast cancer (TNBC) treatment because the disease lacked the molecular targets that transformed treatment in other breast cancer subtypes. That treatment paradigm is no longer the whole story. TNBC has become one of the most active areas... Continue reading
Return to previous page
Tag: Breast Cancer Treatment Landscape
A Decade of Reinvention There was a time when a HER2-positive breast cancer diagnosis carried a particularly difficult outlook. The biology was aggressive, treatment options were limited, and metastatic disease was often approached with the expectation of relatively short disease control. That picture has changed... Continue reading
More
More
- Report & Insights
- Strategy Products
Strategy Products
- Consulting Services
- Media
Media
